Reports & Analytics
Cross-study insights — updated in real time.
Active Studies
2
↑ Both enrolling
Total Subjects
2
↑ 100% active
Adverse Events
4
All Grade 1–2
Audit Events
152
↑ 110 + 42
Data Completion by Study
Osimertinib / FLAURA268%
22 forms · 15 visits · TEST-001
PLANETTE Study54%
9 forms · 7 visits · TEST-001
Completion by Form Category
Adverse Events Summary
4
Total AEs
4
Grade 1–2
0
Grade 3–5
| Event | Grade | Study | Status |
|---|---|---|---|
| Nausea | 1 | FLAURA2 | Recovering |
| Fatigue | 1 | PLANETTE | Recovering |
| Headache | 1 | FLAURA2 | Resolved |
| Decreased Appetite | 2 | PLANETTE | Ongoing |
Hemoglobin Trend — TEST-001 (FLAURA2)
13.8
Scr
13.2
C1D1
12.8
C2D1
13.0
C3D1
Normal range: 12.0–17.0 g/dL · Trending within acceptable limits
Vital Signs Trend — TEST-001 (FLAURA2)
| Visit | SBP | DBP | HR | Temp |
|---|---|---|---|---|
| Screening | 118 | 76 | 72 | 36.7°C |
| C1 D1 | 122 | 78 | 74 | 36.8°C |
| C2 D1 | 124 | 80 | 76 | 37.0°C |
| C3 D1 | 121 | 77 | 73 | 36.9°C |
All values within normal limits. No clinically significant changes.
Audit Activity Over Time
Jan 8Jan 15Jan 22Jan 29Feb 5Feb 14Feb 22Mar 1
■ FLAURA2 (110)
■ PLANETTE (42)
Total 152 events across both studies